Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.72 |
| ▸ | MEN1 | O00255 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13028451 | 0.92 | NHERF1 (0.73) | NHERF1KMT2AMEN1SMN1; SMN2TSHR | |
| SCHEMBL22125328 | 0.89 | NHERF1 (0.65) | NHERF1KMT2AMEN1SMN1; SMN2TSHR | |
| SCHEMBL10420649 | 0.89 | NHERF1 (0.80) | NHERF1KMT2AMEN1SMN1; SMN2TSHR | |
| SCHEMBL21761420 | 0.85 | ALDH1A1 (0.69) | KMT2AMEN1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL1726857 | 0.85 | LMNA (0.76) | NHERF1KMT2ASMN1; SMN2TSHRMAPT | |
| SCHEMBL2827825 | 0.85 | SMN1; SMN2 (0.71) | KMT2AMEN1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9777072 | 0.84 | AR (0.62) | NHERF1KMT2AMEN1SMN1; SMN2TSHR | |
| SCHEMBL7791354 | 0.84 | PLAU (0.72) | NHERF1KMT2AMEN1SMN1; SMN2TSHR | |
| SCHEMBL28280869 | 0.83 | NHERF1 (0.71) | NHERF1KMT2AMEN1SMN1; SMN2TSHR | |
| SCHEMBL11395367 | 0.83 | PKM (0.61) | NHERF1KMT2AMEN1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793806-B2 | Pyruvate kinase activators for use in therapy | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793806-B2 | Pyruvate kinase activators for use in therapy | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023173136-A2 | SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | WO | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210220351-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210198206-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-10988448-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200289502-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-10632114-B2 | Pyruvate kinase activators for use in therapy | AGIOS PHARMACEUTICALS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20160106742-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. | 2016-04-21 | — | — | US | disclosed |
| US-9193701-B2 | Pyruvate kinase activators for use in therapy | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140323467-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8785450-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140194402-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010130638-A1 | SULFONAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2010-11-18 | — | — | WO | disclosed |
| US-6251917-B1 | Benzamidoaldehydes and their use as cysteine protease inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-26 | — | — | US | disclosed |
| CN-1238761-A | benzamide aldehydes and their use as cysteine protease inhibitors | BASF AG (DE) | 1999-12-15 | — | — | CN | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106742-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | NHERF1 3406/4885KMT2A 1401/4885MEN1 3741/4885 |
| US-11793806-B2 | Pyruvate kinase activators for use in therapy | PCK1, PDK3, PDK2 | NHERF1 3406/4885KMT2A 1401/4885MEN1 3741/4885 |
| US-20210220351-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | NHERF1 3406/4885KMT2A 1401/4885MEN1 3741/4885 |
| US-10988448-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | NHERF1 2622/4885KMT2A 751/4885MEN1 3010/4885 |
| US-20200289502-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | NHERF1 3406/4885KMT2A 1401/4885MEN1 3741/4885 |
| US-20210198206-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | NHERF1 2622/4885KMT2A 751/4885MEN1 3010/4885 |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | NHERF1 2622/4885KMT2A 751/4885MEN1 3010/4885 |
| US-20140323467-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | NHERF1 2622/4885KMT2A 751/4885MEN1 3010/4885 |
| US-20140194402-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | NHERF1 3406/4885KMT2A 1401/4885MEN1 3741/4885 |
| US-10632114-B2 | Pyruvate kinase activators for use in therapy | PCK1, PDK3, PDK2 | NHERF1 3406/4885KMT2A 1401/4885MEN1 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.